RhinoCyte™, Inc. is a biotechnology company founded in 2005. RhinoCyte will be a leader in the advancement of cell based therapies by providing innovative auto
RhinoCyte’s lead product is an autologous progenitor cellular replacement or enhancement therapy termed RhinoCytes for Spinal Cord Injury. The product promotes recovery of cell damage resulting from degenerative neurological diseases or traumatic injury. SCI affects more than 365,000 patients in the United States, with 13,000 new cases annually. The annual total costs for SCI exceed $26 Billion.
RhinoCyte’s technology will also benefit patient